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ARTICLE
Mutations in GDP-Mannose Pyrophosphorylase B
Cause Congenital and Limb-Girdle Muscular Dystrophies
Associated with Hypoglycosylation of a-Dystroglycan
Keren J. Carss,1,30 Elizabeth Stevens,2,30 A. Reghan Foley,2 Sebahattin Cirak,2,3 Moniek Riemersma,4,5,6
Silvia Torelli,2 Alexander Hoischen,6 Tobias Willer,7 Monique van Scherpenzeel,5 Steven A. Moore,8
Sonia Messina,9 Enrico Bertini,10 Carsten G. Bo¨nnemann,11 Jose E. Abdenur,12,13 Carla M. Grosmann,14
Akanchha Kesari,3 Jaya Punetha,3,15 Ros Quinlivan,2,16 Leigh B. Waddell,17 Helen K. Young,18,19
Elizabeth Wraige,20 Shu Yau,21 Lina Brodd,21 Lucy Feng,2 Caroline Sewry,2,22 Daniel G. MacArthur,23,24
Kathryn N. North,17,25,26 Eric Hoffman,3,15 Derek L. Stemple,1 Matthew E. Hurles,1
Hans van Bokhoven,27,28 Kevin P. Campbell,7 Dirk J. Lefeber,4,5 UK10K Consortium, Yung-Yao Lin,1,29
and Francesco Muntoni2,*
Congenital muscular dystrophies with hypoglycosylation of a-dystroglycan (a-DG) are a heterogeneous group of disorders often asso-
ciated with brain and eye defects in addition to muscular dystrophy. Causative variants in 14 genes thought to be involved in the glyco-
sylation of a-DG have been identified thus far. Allelic mutations in these genes might also cause milder limb-girdle muscular dystrophy
phenotypes. Using a combination of exome and Sanger sequencing in eight unrelated individuals, we present evidence that mutations
in guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B (GMPPB) can result in muscular dystrophy variants with
hypoglycosylated a-DG. GMPPB catalyzes the formation of GDP-mannose from GTP and mannose-1-phosphate. GDP-mannose is
required for O-mannosylation of proteins, including a-DG, and it is the substrate of cytosolic mannosyltransferases. We found reduced
a-DG glycosylation in the muscle biopsies of affected individuals and in available fibroblasts. Overexpression of wild-type GMPPB in
fibroblasts from an affected individual partially restored glycosylation of a-DG. Whereas wild-type GMPPB localized to the cytoplasm,
five of the identified missense mutations caused formation of aggregates in the cytoplasm or near membrane protrusions. Additionally,
knockdown of theGMPPB ortholog in zebrafish caused structural muscle defects with decreasedmotility, eye abnormalities, and reduced
glycosylation of a-DG. Together, these data indicate that GMPPB mutations are responsible for congenital and limb-girdle muscular
dystrophies with hypoglycosylation of a-DG.
Introduction
Congenital muscular dystrophy (CMD) represents a clini-
cally and genetically heterogeneous group of neuromus-
cular disorders characterized by the onset of muscle
weakness, often associated with limb contractures, at birth
or within the first few months of life. A major subgroup of
CMD is associated withmutations in genes involved in the
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glycosylation of a-dystroglycan (a-DG) and is commonly
referred to as a secondary dystroglycanopathy. a-DG is a
peripheral-membrane protein that is part of the dystro-
phin-associated glycoprotein complex, which provides a
link between proteins located in the extracellular matrix
and proteins located in the cytoplasm immediately
beneath the plasma membrane. Dystroglycan is translated
from a single mRNADAG1 (MIM 128239) and cleaved into
a and b subunits.1,2 Extracellular a-DG noncovalently
binds to the transmembrane protein b-dystroglycan
(b-DG), which in turn associates with intracellular proteins
involved in force and signal transduction. In contrast,
a-DG binds a number of extracellular ligands, including
laminins, perlecan, agrin, neurexin, pikachurin, and
slit.2–5 Extensive and tissue-specific glycosylation is essen-
tial for the binding of a-DG to these extracellular-matrix
ligands.6–10 Recessive mutations in DAG1 have been
identified in a single case of mild muscular dystrophy,
suggesting the existence of a primary subset of dystroglyca-
nopathies.11
Mutations in 14 genes are currently known to cause sec-
ondary dystroglycanopathies. POMT1 (MIM 607423),
POMT2 (MIM 607439), and POMGNT1 (MIM 606822)
encode proteins with confirmed involvement in O-man-
nosylation.3,4,12,13 DPM2 (MIM 603564), DPM3 (MIM
605951), and DOLK (MIM 610746) encode proteins
involved in the synthesis of dolichol-phosphate mannose
(Dol-P-Man), which is the essential mannose donor
required for mannosylation.14–16 LARGE (MIM 603590)
encodes a bifunctional enzyme with xylosyl and glucuro-
nyltransferase activities.17,18 B3GNT1 (MIM 605581) and
B3GALNT2 (MIM 610194) encode glycosyltransferases
whose exact role in O-mannosylation remains un-
clear.19,20 On the basis of protein sequence homology,
FKTN (MIM 607440), FKRP (MIM 606596), and GTDC2
(MIM 614828) are thought to encode glycosyltransferases,
although their enzymatic function has not been conclu-
sively demonstrated.21–23 Finally, mutations in the largely
uncharacterized genes ISPD (MIM 614631) and TMEM5
(MIM 605862) can also cause secondary dystroglycanopa-
thies.24–28
Mutations in the aforementioned genes were originally
identified almost invariably in individuals affected by
severe CMD variants—with associated structural brain
and eye abnormalities—such as Walker-Warburg syn-
drome (WWS [MIM 236670]), Fukuyama CMD (FCMD
[MIM 253800]), and muscle-eye-brain disease (MEB [MIM
253280]) or forms with exclusive skeletal-muscle involve-
ment, such as CMD type 1C (MIM 606612). Subsequently,
milder allelic mutations in several of these genes were
identified in later-onset forms of limb-girdle muscular dys-
trophy (LGMD), such as in the common LGMD2I variant
(MIM 607155). Muscle pathology in all of these conditions
shares dystrophic changes and defective glycosylation of
a-DG, which can be assessed on immunohistochemistry
or immunoblot with IIH6 or VIA4-1 antibodies, which
recognize disease-relevant glycoepitopes on a-DG.9
The dystroglycanopathies represent one of the most
common forms of muscular dystrophy, and mutations in
POMT1, POMT2, POMGNT1, FKRP, or ISPD are the most
frequent cause.24,27 Mutations in the known genes cannot
explain all cases.27,29–31 In this study, we identified muta-
tions in guanosine diphosphate mannose (GDP-mannose)
pyrophosphorylase B (GMPPB) in eight dystroglycanop-
athy cases affected by either CMD or LGMD phenotypes.
Functional analyses using cellular and zebrafish models
implicated GMPPB (also known as mannose-1-phosphate
guanyltransferase beta [Enzyme Commission number
2.7.7.13]) in the glycosylation of a-DG.
Subjects and Methods
Clinical Presentation of Subjects
The main clinical features of the eight unrelated cases (P1–P8) re-
ported in this manuscript are presented in Table 1. The spectrum
of severity observed in these cases ranges from a child with a clas-
sical CMD presentation characterized by muscle weakness at birth
and motor and cognitive developmental delays including ataxia,
absent speech development, and inability to walk unsupported
(P1) to children presenting in the first few months of life with hy-
potonia, muscle weakness, delayed acquisition of independent
mobility, and mild intellectual disability but normal brain struc-
ture (P3 and P4) to children presenting in the first few years of
life withmild limb-girdle weakness andmild intellectual disability
(P2 and P8) to a child with normal cognitive function following
a LGMD disease course (P7). Commonly associated features
included epilepsy (P2, P5, P6, and P8), microcephaly (P1, P2, P3,
and P8), cataracts (P3, P4, and P8), strabismus (P3, P4, and P5)
(Figure S1, available online), and nystagmus (P4 and P8). Brain
MRI showed a range of abnormalities, including structural defects
such as cerebellar and pontine hypoplasia (Figure 1), but it was
normal in P2, P3, P4, and P8 (it was not performed in P7), who
were all affected by a milder variant. Progression of muscle weak-
ness was clearly observed, and P4 lost ambulation during child-
hood. Evidence of combined cardiorespiratory compromise was
evident by the age of 10 years in P8, and features of cardiac
involvement, including a long QT interval and left ventricular
dilation, were documented in P3 and P4, respectively. P5 and P6,
affected by CMD with cerebellar involvement, have previously
been described in detail (affected individuals 1 and 2, respectively,
in Messina et al.32).
The institutional review board (IRB) of the University College
London Institute of Child Health and Great Ormond Street
Hospital in the United Kingdom approved the study of P1, P2,
and P7 and all cellular work. Informed consent and local-re-
view-board approval were in accordance with the UK10K project
ethical framework. We recruited and analyzed P3 under Chil-
dren’s National Medical Center (CNMC) IRB protocol 2405,
which was reviewed and approved by the Office for the
Protection of Human Subjects at the CNMC, Washington, DC,
USA. P3 provided informed consent for publication of clinical
photographs. The IRB of the University of Iowa approved the
study of P4 (IRB ID 200510769). The study of P5 and P6 was
performed under ethical approval number 489/2012 and protocol
number GUP1100A1. The study of P8 was approved by the
Sydney Children’s Hospitals Network Human Research Ethics
Committee.
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Table 1. Clinical Features of Individuals with GMPPB Mutations
Case
P1 P2 P3 P4 P5a P6a P7 P8
Gender male female male female female female male male
Current age 8 years 12 years 16 years 13 years died at 14 years 10 years 6 years 18 years
Ethnicity Pakistani Indian Mexican Mexican Italian Italian English Egyptian
Prenatal findings oligohydramnios none none decreased fetal
movement
decreased fetal
movement
decreased fetal
movement
none none
Age at presentation birth birth 2 weeks birth 4 months 4 months 4 years 2.5 years
Presenting symptoms increased tone;
microcephaly; cleft
palate; feeding
difficulties
hypotonia;
microcephaly
increased tone,
then hypotonia;
microcephaly;
cataracts; torticollis;
ileal atresia
hypotonia; feeding
difficulties
poor head control poor head control mild exercise
intolerance
difficulty in climbing
stairs; microcephaly
Maximal motor
ability
walking with support
(at 3 years)
running walking (at 3.5 years) walking (at 3 years) unable to sit sitting (at 2 years) running running
Main neurological
features
severe intellectual
delay; sensorineural
hearing loss; ataxia
mild intellectual
delay; epilepsy
mild intellectual delay mild intellectual delay severe intellectual
delay; drug-resistant
epilepsy; motor delay
severe intellectual
delay; drug-resistant
epilepsy; motor delay
normal cognitive
function
mild intellectual
delay; epilepsy
Ophthalmologic
findings
retinal dysfunction (on
electroretinogram)
none cataracts; strabismus;
ptosis
cataracts; strabismus;
intermittent
nystagmus; ptosis
strabismus none none cataracts; nystagmus
Cardiorespiratory
findings
none none long QT syndrome left ventricular
dilatation
none none none wandering atrial
pacemaker;
cardiomyopathy;
respiratory
insufficiency
Maximum CK (U/l) 2,974 4,504 7,323 8,450 630 720 3,000 5,200
Brain MRI findings pontine and cerebellar
hypoplasia
no structural
abnormality
no structural
abnormality
no structural
abnormality
cerebellar hypoplasia cerebellar hypoplasia not performed no structural
abnormality
Diagnosisb MEB- and/or FCMD-
like
LGMD-MR CMD-MR CMD-MR CMD-CRB CMD-CRB LGMD LGMD-MR
Abbreviations are as follows: CK, creatine kinase; CMD-CRB, congenital muscular dystrophy with cerebellar involvement; CMD-MR, congenital muscular dystrophy with mental retardation; FCMD, Fukuyama congenital
muscular dystrophy; LGMD-MR, limb-girdle muscular dystrophy with mental retardation; MEB, muscle-eye-brain disease; and WWS, Walker-Warburg syndrome.
aThe phenotypes of P5 and P6 have previously been described in detail.32
bDiagnostic categories have previously been described.31
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Genetic Analysis
We sequenced the exome of P1 within the UK10K project and
called and filtered variants as previously described.26
P3 underwent exome sequencing at the CNMC according to the
following protocol: 1 mg of DNA was sheared to 200 bp with a
Covaris S220 (Covaris) and was prepared with TruSeq DNA Sample
Preparation and TruSeq Exome Enrichment Kits (Illumina) accord-
ing to the manufacturer’s instructions. We sequenced it by using a
HiScanSQ (Illumina) with 200 cycles and paired-end multiplexed
sequencing with read lengths of 100 bp in each direction. The
mean coverage was 503. We used CASAVA 1.8.1 for initial demul-
tiplexing and file conversion, and we aligned sequences to the
human reference genome (UCSC Genome Browser hg19) with
the use of NextGENe (SoftGenetics) and annotated calls by using
the dbNSFP database.33
P5 and P6 were exome sequenced as previously described, and
genetic variants were further prioritized on the basis of a filter con-
sisting of glycosylation genes.24,34
For P8, exome capture was performed on genomic DNA with
the Agilent Whole Exome SureSelect v.2 kit according to the
manufacturer’s instructions. Captured exome DNA was then sub-
jected to Illumina sequencing. Reads were processed by Picard
and aligned to the human reference genome (hg19) with the
Burrows-Wheeler Aligner,35,36 and then calling of single-nucleo-
tide variants (SNVs) and small indels was performed with the
GATK toolkit.37 Variants were annotated with a modified version
of the Ensembl Variant Effect Predictor38 and filtered for inheri-
tance patterns and predicted functional severity with the xBrowse
web server.
We used standard Sanger-sequencing protocols to verify all the
mutations identified by exome sequencing and to discover muta-
tions in P2, P4, and P7 (data not shown). Primer sequences are
available upon request.
Muscle Pathology and Immunoblots
Histological, histochemical, and immunohistochemical studies
on skeletal-muscle biopsies were performed as described previ-
ously,20,39 except that in addition, an antibody against the
300 kDa fragment of laminin-a2 (4H8-2)40 was used.
Immunoblotting of P1 muscle protein lysate and P1, P2, P4, P5,
and P6 fibroblast protein lysate was performed as previously
described.20 For P4 muscle-biopsy samples, we enriched glyco-
proteins with wheat germ agglutinin (WGA) and immuno-
blotted these on polyvinylidene difluoride (PVDF) membranes as
described.9 Membranes were developed with infrared-dye-conju-
gated secondary antibodies (Pierce Antibodies) and scanned
with an Odyssey infrared imaging system (LI-COR Bioscience).
Laminin-overlay assays were performed as previously described.9
The monoclonal antibodies to the fully glycosylated form of
a-DG (IIH6), core a-DG (G6317), and b-DG (AP83) have been char-
acterized previously.25,41,42
Expression Studies of GMPPB
In order to study the transcription profile of GMPPB, we reverse
transcribed an adult tissue RNA panel (Life Technologies) and fetal
tissue RNA panel (Agilent Technologies) by using a one-step RT-
PCR kit (QIAGEN) according to the manufacturer’s instructions.
Primers are listed in Table S1.
In order to assess the localization of wild-type GMPPB and
GMPPB carrying the amino acid changes observed in affected in-
dividuals, we amplified its coding sequence (RefSeq accession
number NM_021971.1) from a full-length cDNA IMAGE clone
of human GMPPB (IRAUp969D1013D, Source Bioscience). The
product was cloned into the pcDNA3.1/V5-His TOPO expression
vector (Life Technologies) according to themanufacturer’s instruc-
tions. We introduced mutations identified in the individuals
with CMD into GMPPB pcDNA 3.1/V5-His TOPO by using
QuickChange II site-directed mutagenesis (Agilent Technologies).
Primers are listed in Table S2. We assessed the localization of
the V5-FITC-tagged wild-type and altered GMPPB constructs in
cultured C2C12 myoblasts as previously described20 by using the
V5-FITC antibody (Life Technologies).
Effect of GMPPB Mutations on a-DG Glycosylation
Assessed by Flow Cytometry
In order to quantify the amount of a-DG glycosylation on fibro-
blasts of available affected individuals and healthy control fibro-
blasts, we used IIH6 (Merck Millipore) to perform flow cytometry
as previously described.20 To calculate the mean fluorescence in-
tensity (MFI) of each population of fibroblasts, we first subtracted
the background-intensity values obtained when cells were incu-
bated only with IgM (biotinylated) and streptavidin-PE. The addi-
tion of the primary antibody allowed us to obtain the intensity
values (calculated with FlowJo software [Tree Star]) for the IIH6-
positive fibroblasts. Statistical analysis was performed with the
use of unpaired two-tailed t tests.
Zebrafish Knockdown
We extracted zebrafish RNA at different developmental stages
and carried out reverse transcription and PCR as previously
described.20 Primer sequences are in Table S3. To knock down
zebrafish gmppb, we obtained a splice-blocking morpholino oligo-
nucleotide (MO) (sequence 50-GGACCAGCTGAAAACAGAAACA
GAT-30) from Gene Tools. This was injected into 1- to 4-cell stage
Tuebingen Long Fin zebrafish embryos. Unless otherwise stated,
it was coinjected with p53 MO. The sequences of the p53 and
dag1 MOs have previously been described.43,44
To assess muscle pathology in zebrafish, we used immunofluo-
rescent imaging as previously described44 to study the following
proteins: filamentous actin with the use of Alexa-Fluor-594-conju-
gated phalloidin (Life Technologies) and b-DG (monoclonal,
NCL-b-DG from Leica Microsystems). We also performed an
Evans blue dye (EBD) assay and immunoblotting of zebrafish
Figure 1. MRI Reveals Structural Brain
Abnormalities in P1 and P6
On sagittal views of T1-weighted MRI,
there is evidence of cerebellar hypoplasia
in P6 (A) at 2 years of age and pontine
and cerebellar hypoplasia in P1 (C) at
6 years of age. Coronal views reveal evi-
dence of cerebellar inferior vermian hypo-
plasia on T2-weighted MRI in P6 (B) and
on T1-weighted MRI in P1 (D).
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microsome-pellet proteins as previously described and quantified
the immunoblot results by using ImageJ software.20,45 To assess
the significance of the results of the EBD assay, we used unpaired
two-tailed t tests.
Results
Identification and Characterization of GMPPB
Variants in Individuals Affected by CMD
We performed exome sequencing in P1, who is affected by
a severe form of CMD with brain involvement, as part of
the UK10K rare cohort, and variants were filtered as out-
lined in Table S4. We identified 22 high-quality loss-of-
function heterozygous variants in P1. Only two of these
candidate genes showed possible compound heterozygosi-
ty and are therefore consistent with the expected recessive
mode of inheritance with unrelated parents: alpha 1, 2-
mannosidase (MAN1B1 [MIM 604346]) and GMPPB.
Mutations in MAN1B1 can cause nonsyndromic and
syndromic intellectual disability without microcephaly.46
Because neither muscular dystrophy nor brain malforma-
tion is a feature of MAN1B1 mutations, it is unlikely that
these variants explain the phenotype of P1. GMPPB cata-
lyzes the formation of GDP-mannose from mannose-1-
phosphate and GTP.47 GDP-mannose is required in four
glycosylation pathways (Figure 2), including O-mannosy-
lation of membrane and secretory glycoproteins, such as
a-DG. Mutations in other members of this pathway are
known to cause dystroglycanopathy.14,15 We therefore
considered variants in GMPPB as the likely cause of disease
in P1.
RT-PCR of human fetal and adult RNA from various tis-
sues showed that GMPPB is transcribed as two isoforms
in humans (RefSeq NM_013334.2 and NM_021971.1). In
contrast to NM_013334.2, NM_021971.1 was strongly ex-
pressed in all tested tissues, including brain and skeletal
muscle (Figure S2). All listed mutations correspond to
NM_021971.1.
The GMPPB mutations in P1 are c.220C>T (p.Arg74*)
and c.1000G>A (p.Asp334Asn). Through an international
collaborative effort, we identified recessive GMPPB muta-
tions in seven further dystroglycanopathy cases (P2–P8)
with phenotypes ranging from severe CMD with the
inability to walk to severe intellectual disability and epi-
lepsy to later-onset phenotypes resembling LGMD with
only mild intellectual disability or no evidence of brain
involvement. P2 has the compound heterozygous GMPPB
mutations c.64C>T (p.Pro22Ser) and c.1000G>A (p.As-
p334Asn). P3, P4, and P8 carry the homozygous
c.553C>T (p.Arg185Cys) mutation. P5 and P6 carry the
c.95C>T (p.Pro32Leu) and c.860G>A (p.Arg287Gln) mu-
tations, and P7 has the heterozygous mutations c.79G>C
(p.Asp27His) and c.988G>A (p.Val330Ile). No MAN1B1
variants were found in the other individuals who were
exome sequenced (P3, P5, P6, and P8). None of these indi-
viduals are related, and although the recurrent mutations
in individuals of related ethnic origin could be due to
founder effects (i.e., P1 and P2 share one variant, and P3
and P4 are homozygous for the same change), we also
found the latter change in P8, who is of a completely
different origin. The asymptomatic parents of P1, P2, P5,
P6, P7, and P8 and the mother of P4 were found to be het-
erozygous carriers of the variants described.
Of the eight variants described, five have not been previ-
ously reported. The three that have (c.860G>A, c.79G>C,
and c.988G>A) are very rare and have a minor allele fre-
quency of less than or equal to 0.001 according to data
from the UK10K twins cohort or the ClinSeq study
Figure 2. GMPPB Function, Structure, and Identified Substitutions
(A) The function of GMPPB in glycosylation pathways.
(B) GMPPB has 360 amino acids and two predicted Pfam functional domains: a nucleotidyl transferase domain and a bacterial transferase
hexapeptide domain. In this schematic diagram, the blocks represent regions encoded by exons and the substitutions identified in in-
dividuals with dystroglycanopathy are shown. The following abbreviation is used: H, homozygous.
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(Table S5). This is compatible with CMD’s frequency,
which has been estimated to be around 1 in 50,000–
100,000.48
We performed alignments by using the human GMPPB
sequence against the genomes of five diverse eukaryotic
species and found that each has a GMPPB ortholog
that is at least 63.8% identical to the human sequence
(Table S6 and Figure S3). We found that of the eight vari-
ants described, five (c.64C>T, c.95C>T, c.1000G>A,
c.553C>T, and c.988G>A) affect amino acids that are
conserved throughout all species tested, suggesting func-
tional importance (Figure S3). Although the amino acid
affected by the c.220C>T mutation in P1 is not highly
conserved, it is located in the nucleotidyl transferase
domain (Pfam ID PF00483) (Figure 2), and the mutation
is predicated to cause a severely truncated protein in addi-
tion to nonsense-mediated mRNA decay. Of the eight var-
iants described, five are within the nucleotidyl transferase
domain. Interestingly, all affected individuals have at least
one alteration in this domain (Figure 2).
Individuals with GMPPB Mutations Have
Hypoglycosylated a-DG in Muscle Biopsy
To assess the muscle pathology, we examined muscle
biopsies of all affected individuals except P5 and P8. In all
cases, the muscle biopsies showed features of a muscular
dystrophy with abnormal variation in fiber size, necrosis,
regeneration, excess endomysial connective tissue, and an
increase in internal nuclei and inflammatory infiltrates
(Figure 3 and Figures S4 and S5). Immunolabeling of
laminin-a2 with antibodies to both the 80 and 300 kDa
fragments showed reduced labeling of some fibers, but
not in all cases (data not shown). Labeling of b-DG was
invariably normal, whereas labelingwith the IIH6 antibody
was variably reduced. In P3 and P4, the reduction of the gly-
Figure 3. a-DG Glycosylation Is Reduced
in Muscle Biopsies of Affected Individuals
with GMPPB Mutations
An examination of skeletal-muscle cryo-
sections from the control (A, E, I, and M),
P1 (B, F, J, and N), P2 (C, G, K, and O),
and P7 (D, H, L, and P) revealed that glyco-
sylated a-DG immunolabeling (assessed
with IIH6) was moderately reduced in indi-
viduals (P1, P2, and P7) withGMPPBmuta-
tions and that b-DG and core a-DG were
well preserved. Stains are as follows: hema-
toxylin and eosin (A–D), b-DG (E–H), a-DG
IIH6 (I–L), and a-DG core (M–P).
cosylated epitope on a-DG was also
confirmed with the VIA4-1 antibody,
whereas the staining obtained with
a-DG GT20ADG, a goat polyclonal
antibody, which recognizes the core
protein, was normal (Figure S4).
Immunoblots from skeletal-muscle
biopsies confirmed the reduction in
glycosylated a-DG in P1, P4, and P8 compared to the con-
trol (Figure 4 and Figure S6); in P4, the lower-molecular-
weight band identified by the core a-DG antibody and
the reduction with the laminin overlay also suggested
hypoglycosylated a-DG (Figure 4). Immunoblotting of
fibroblast lysate with the IIH6 antibody showed that there
was substantially less a-DG glycosylation in P1, P2, P4, and
P5 than in controls and only a lesser reduction in P6
(Figure 4). Flow cytometry showed that there was signifi-
cantly less glycosylated a-DG in fibroblasts from P1, P2,
P4, P5, P6, and P7 (p < 0.05) than in controls, as shown
by the MFI of IIH6, as well as the percentage of fibroblasts
that were positive for the IIH6 epitope (Figure 4).
Next, we transfected fibroblasts from P1 with wild-type
GMPPB cDNA to determine whether the reduced amount
of a-DG glycosylation of this individual was related to
dysfunctional GMPPB. The amount of glycosylated a-DG
was increased as determined by the average MFI of IIH6
with the use of flow cytometry (Figure S7 and Table S7),
suggesting that wild-type GMPPB complemented the
altered GMPPB. Similar to the wild-type healthy control
fibroblasts, 23.5% of the total transfected population of
fibroblasts had a higher MFI (76.2) than the untrans-
fected fibroblasts. Transfection of the wild-type gene into
control fibroblasts did not alter the MFI of IIH6 (data not
shown). These results suggest that GMPPB mutations are
the cause of reduced a-DG glycosylation for P1.
In view of the role of GMPPB in multiple glycosylation
reactions (Figure 2), we tested N-glycosylation of serum
transferrin, abnormal in congenital disorders of glycosyla-
tion (CDG). For all affected individuals, routine diagnostic
screening for CDG by transferrin isoelectric focusing
showed normal results, which was confirmed by highly
sensitive mass spectrometry of intact transferrin for P6
(Figure S8).
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Subcellular Localization of Wild-Type and Mutant
GMPPB
To further elucidate the effects of the missense muta-
tions found in P1–P8, we introduced the mutations
c.1000G>A, c.64C>T, c.553C>T, c.95C>T, c.860G>A,
c.79G>C, and c.988G>A into wild-type GMPPB and
studied the localization of the resultant altered proteins in
C2C12 myoblasts. Wild-type GMPPB, a soluble enzyme,49
localized to the cytoplasm (Figure 5). The mutations
c.1000G>A (found in P1 and P2), c.95C>T and
c.860G>A (both found in P5 and P6), and c.988G>A
(found in P7) caused the protein to form aggregates within
the cytoplasm (Figure 5). The mutation c.64C>T (found in
P2) caused GMPPB to aggregate near membrane protru-
sions into the cytoplasm (Figure 5). The mutations
c.553C>T (found in P3, P4, and P8) and c.79G>C (found
Figure 4. Immunoblots and Flow Cytometry Confirm that a-DG Glycosylation Is Reduced in Muscle and Fibroblasts of Affected
Individuals with GMPPB Mutations
(A) Immunoblot analysis of skeletal-muscle protein lysates from P1 and P4. (Ai) The membrane was incubated with IIH6 and b-DG
antibodies. P1 shows a reduction in a-DG glycosylation. (Aii) For P4, WGA-enriched skeletal-muscle homogenates were used, and the
immunoblot was probed with IIH6, a-DG core, and b-DG antibodies, as well as by laminin overlay. b-DG appears as a possible doublet
in P1 and P4 (and P8, Figure S6).
(B) Immunoblot analysis of fibroblast protein lysate from P1, P2, P4, P5, and P6. The membrane was incubated with IIH6 and b-DG
antibodies. a-DG glycosylation is reduced in fibroblasts of individuals with GMPPB mutations.
(C) Flow cytometry of fibroblasts revealed reduced a-DG glycosylation for P1, P2, P4, P5, P6, and P7. This histogram shows the MFI of
IIH6 staining for a secondary-only control, P1, P2, P4, P5, P6, P7, and a control fibroblast cell line. TheMFI of the populations positive for
IIH6 were 88.95 for the control, 19.6 for P1, 30.15 for P2, 26.34 for P4, 14.60 for P5, 28.63 for P6, and 45.3 for P7 (n¼ 6 for all). There was
a statistically significant (p< 0.05) reduction in a-DG glycosylation in fibroblasts from the six individuals tested compared to controls, as
determined by the average MFI of IIH6. The percentage of fibroblasts (out of a minimum of 10,000) that were positive for the IIH6
epitope was 85% for the control, 27% for P1, 16% for P2, 45% for P4, 60% for P5, 50% for P6, and 65% for P7. A IIH6-positive gate
was set up with a negative control (where primary antibody was omitted) for all fibroblast cell lines tested and the control.
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in P7) caused GMPPB to remain evenly distributed
throughout the cytoplasm and to have no discernible
changes compared with wild-type GMPPB (Figure 5).
Knockdown of the GMPPB Ortholog in Zebrafish
Embryos Recapitulates Features Characteristic of
Dystroglycanopathies
In order to gather additional evidence of the role ofGMPPB
in vivo, we studied zebrafish (Danio rerio) gmppb. There is
high sequence homology between the proteins encoded
by these genes (81.4% identical; Table S6). We confirmed
by RT-PCR that zebrafish gmppb is expressed throughout
early embryonic development (Figure S9). To knock
down zebrafish gmppb, we used a splice-blocking MO
that targets the intron 4-exon 5 boundary within the
nucleotidyl transferase domain (Figure S10).
Subsequently, we extracted RNA from wild-type and
MO-injected embryos and performed RT-PCR with primers
flanking the MO binding site (Figure S10). Compared to
wild-type embryos, gmppb-MO-injected embryos (mor-
phants) showed a clear reduction of the normal gmppb
transcripts, whereas the amount of a housekeeping gene
(actb1) remained roughly equivalent (Figure S10). This
suggests that the gmppb MO specifically knocks down
gmppb.
Morphologically, gmppb morphants were shorter than
wild-type uninjected embryos at 48 hr postfertilization
(hpf) and often had bent tails. Other phenotypes included
hypopigmentation, micropthalmia, hydrocephalus, and
reduced motility (Figure 6, Figure S11, and data not
shown). The difference in diameter between the eyes of
wild-type and gmppb morphant embryos was statistically
significant (p < 1 3 107; Figure S11). Although none of
our cases reported micropthalmia, this is a phenotype
that is common in individuals with severe forms of
CMD, such as WWS and MEB.3,4,20,23–25
To characterize muscle defects in gmppb-knockdown
zebrafish embryos, we used phalloidin to label filamentous
actin, along with immunostaining with antibodies against
b-DG (which localizes to the myosepta, the connective tis-
sue to which muscle fibers anchor). We observed that the
muscle fibers in gmppb morphants were sparse and disor-
dered. Furthermore, fibers were frequently observed to
span two somites, indicating damage or incomplete devel-
opment of the myosepta (Figure 6).
To further explore themuscle phenotypes in gmppbmor-
phants, we injected EBD into the pericardium of embryos
at 2 days postfertilization. EBD is an azo dye that binds
to proteins such as albumin and is transported in the
serum. It fluoresces upon protein binding and infiltrates
muscle where there are lesions between muscle fibers
(interfiber spaces) or where there is sarcolemmal dam-
age.50 Compared with uninjected control embryos, gmppb
morphants had significantly more EBD accumulation
within interfiber spaces (p < 0.001; Figure 6). In addition,
EBD infiltrated both retracted and some intact muscle
fibers in gmppb-knockdown embryos, suggesting that
Figure 5. GMPPB Mutations Can Cause Mislocalization of
GMPPB in Cultured Myoblasts
C2C12 myoblasts were transfected with GMPPB pcDNA 3.1 V5/
HIS-TOPO that was either wild-type or had the missense mutation
c.1000G>A (p.Asp334Asn), c.64C>T (p.Pro22Ser), c.553C>T
(p.Arg185Cys), c.95C>T (p.Pro32Leu), c.860G>A (p.Arg287Gln),
c.79G>C (p.Asp27His), or c.988G>A (p.Val330Ile). Compared to
the wild-type, the mutations c.1000G>A, c.64C>T, c.95C>T,
c.860G>A, and c.988G>A caused the protein to localize differ-
ently and aggregate, whereas the mutations c.553C>T and
c.79G>C did not visibly alter the subcellular localization of
GMPPB and the enzyme remained distributed evenly in the
cytoplasm.
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sarcolemma integrity was compromised prior to muscle-
fiber breakdown (Figure 6).
Next, we investigated whether the laminin-binding
glycan on a-DG is reduced in gmppb morphants. To do
this, we performed immunoblots with the IIH6 antibody
on membrane proteins enriched from wild-type embryos
and gmppb morphants, as well as dag1 morphants as a
negative control. After normalization to g-tubulin loading
control, gmppbmorphants showed a slight but clear reduc-
tion in IIH6 levels (71% of that of the wild-type embryos)
and dag1 morphants showed a strong reduction in IIH6
(15% of that of the wild-type embryos) (Figure 6). To
confirm this finding, we performed double immunostain-
ing with the IIH6 antibody and an antibody against lami-
nins. In wild-type embryos, laminin and glycosylated
a-DG colocalized at the myosepta. In gmppb morphants,
the IIH6 staining was severely reduced and laminin stain-
ing revealed widened myosepta, indicating a reduction in
glycosylation of a-DG associated with abnormal base-
ment-membrane structure (Figure S12).
Discussion
Here, we report the identification of GMPPB mutations in
eight individuals with dystroglycanopathy by exome
and Sanger sequencing. Immunohistochemistry showed
reduced glycosylation of a-DG in muscle biopsies from
affected individuals, and this finding was confirmed in
available fibroblasts with the use of immunoblotting and
flow cytometry, which revealed a reduction in the IIH6
signal. Transfection of an affected individual’s fibroblasts
Figure 6. Zebrafish Embryos with gmppb Knockdown HaveMorphological Defects, DamagedMuscle, and Hypoglycosylated a-DG at
48 hpf
(A) Bright-fieldmicroscopy of live embryos showsmorphological defects of the gmppb-MO-injected embryos (injected with gmppb splice-
blocking MO 3ng þ p53 MO 6ng) as compared to uninjected wild-type embryos.
(B) Phalloidin staining of filamentous actin (red) and immunostaining with an antibody against b-DG (green).
(C) Live gmppb-MO-injected embryos injected with EBD (red) and imaged by confocal microscopy. Some fibers showed EBD infiltration,
indicating damage to the sarcolemma (green arrow), and other fibers detached from the myosepta and retracted (yellow arrow) and thus
left a space. The following abbreviation is used: DIC, differential interference contrast. The scale bar represents 25 mm.
(D) gmppbmorphants have significantly more interfiber spaces than do wild-type uninjected embryos. The horizontal dotted line shows
the median.
(E) An immunoblot shows a reduction in a-DG glycosylation. Percentage figures indicate the intensity ofmorphant bands relative to that
of the wild-type and are adjusted for the g-tubulin loading control. ‘‘gmppbMO’’ indicates embryos injected with gmppbMO 3ng þ p53
MO 6ng, and ‘‘dag1 MO’’ indicates embryos injected with dag1 translation-blocking morpholino (5 ng).
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with wild-type GMPPB increased a-DG glycosylation,
providing additional evidence that the GMPPB mutations
carried by this individual are pathogenic and cause dystro-
glycanopathy.
Subcellular-localization studies indicated that GMPPB
localizes to the cytosol, in agreement with its role in cyto-
solic synthesis of nucleotide sugars. This is consistent with
the known localization of GDP-MP, theGMPPB ortholog in
the protozoa L. mexicana.49 Assessment of the localization
of altered GMPPB suggested that several of the altered
enzymes formed aggregates within the cytoplasm or close
to membrane protrusions into the cytoplasm and presum-
ably interfered with the enzymatic function. Knocking
down zebrafish gmppb recapitulated several aspects of
the human phenotypes, including muscular dystrophy.
Aspects of the phenotype were similar to those seen
when other dystroglycanopathy genes are knocked down
in zebrafish.20,24,50
Recent studies have revealed new details about a-DG
glycosylation. For example, a highly specific O-mannosy-
lated structure required for a-DG binding to extracellular
ligands has been identified.51,52 Moreover, phosphoryla-
tion of an O-mannosyl glycan in the mucin-like domain
of a-DG is required for its proper function.53 Recent
mass-spectrometry studies have revealed the heterogeneity
and complexity of a-DG O-mannosylation,54,55 a rare type
of glycosylation that is particularly abundant on a-DG and
clearly and specifically disrupted by mutations in well-
characterized O-mannosyltransferase-encoding genes like
POMT1, POMT2, and POMGNT1.3,4,12,13 More recently,
mutations in genes encoding upstream components of
the endoplasmic reticulum (ER) glycosylation pathway
have been demonstrated to also cause dystroglycanopa-
thies.14,15
GMPPB catalyzes the synthesis of GDP-mannose from
GTP and mannose-1-phosphate. GDP-mannose is the sub-
strate of cytosolic mannosyltransferases required for the
synthesis of the core N-glycan structure, and it is required
for the synthesis of Dol-P-Man in the ERmembrane. Dol-P-
Man synthesis is catalyzed by the DPM synthase complex,
consisting of DPM1, DPM2, and DPM3. Dol-P-Man is the
mannose donor required for all four mannosylation
reactions that occur in the ER: O-mannosylation, C-man-
nosylation, N-glycosylation, and glycosylphosphatidyli-
nositol-anchor formation.56 Substitutions in proteins
required for the synthesis of Dol-P-Man could therefore
theoretically perturb any of these pathways. Indeed, indi-
viduals with mutations in DPM2 and DPM3 have, in addi-
tion to a dystroglycanopathy, features evocative of a defect
in N-glycosylation, such as abnormal glycosylation of
transferrin, which is characteristic of CDG.14,15 However,
in all our cases of mutant GMPPB, we found no evidence
of perturbed transferrin glycoforms.
There are a number of possible explanations for this
observation. For example, Dol-P-Man might be used to
different extents in the N-glycosylation and O-mannosyla-
tion pathways. Previous research has shown that two
enzymes in the glycosylation pathway compete for a com-
mon substrate and can use their substrates differentially,
supporting this hypothesis.57 Alternatively, N-glycosyla-
tion could occur before O-mannosylation and the amount
of Dol-P-Man would therefore be depleted by N-glycosyla-
tion before O-mannosylation starts.
Given what we know about the importance of glycosyl-
ation for a-DG function, it appears likely that the patho-
genic mutations we have identified in GMPPB impair
GMPPB function and thereby reduce the amount of
GDP-mannose available for O-mannosylation of a-DG
and ultimately cause the CMD phenotype. Although the
full spectrum of clinical phenotypes associated with muta-
tions in GMPPB has yet to be seen, the eight individuals
described here demonstrate a wide range of muscle
weakness, from a mild LGMD-like phenotype to a severe
MEB- and/or FCMD-like phenotype, as well as cardiac
involvement in the oldest surviving individuals; this
phenotype range resembles the spectrum of phenotypes
described for mutations in FKRP, FKTN, and ISPD. Features
that were relatively common in individuals with GMPPB
mutations but rare in other genotypes relate to the
ophthalmologic finding of cataracts, observed not only
in individuals with MEB- and/or FCMD-like phenotypes
but also in individuals with CMD-MR (CMD with mental
retardation) and LGMD-MR (LGMD with mental retarda-
tion) phenotypes.
GMPPB orthologs have been knocked down in various
species, including Saccharomyces cerevisiae, Aspergillus fumi-
gatus, Arabidopsis thaliana, Solanum tuberosum, Trypano-
soma brucei, and Leishmania mexicana.49,58–63 This caused
glycosylation defects and a range of pathogenic pheno-
types from defective cell growth to lethality. This severity
suggests that complete loss of function of GMPPB might
be lethal. In this respect, it is interesting to note that we
did not identify any case with two null alleles, and it is
possible that some GMPPB function was retained in our
cases.
In humans, GMPPB has a paralog, GMPPA. The proteins
encoded by these genes are 30% identical to each other. In
pigs, GMPPB and GMPPA act as a complex (GMPP) to cata-
lyze the synthesis of both GDP-mannose and GDP-Glc
(they have a higher affinity for synthesizing GDP-Glc).
GMPPB alone has a very high affinity for synthesizing
GDP-mannose and a low but detectible affinity for synthe-
sizing GDP-Glc.47 Although to our knowledge the affinity
of GMPPA for synthesizing GDP-Man has not been inves-
tigated, these results suggest some functional overlap
between GMPPA and GMPPB. If this is true for humans,
GMPPA might be able to synthesize some GDP-mannose
in our CMD cases, which could contribute to the unexpect-
edly mild phenotype.
In summary, by using a combination of exome and
Sanger sequencing, we have identified mutations in
GMPPB in eight individuals with a wide spectrum of dys-
troglycanopathy phenotypes, ranging from CMD with
structural brain involvement to LGMD. The spectrum
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and overall frequency of the conditions resulting from
GMPPB mutations appear to be as wide as those reported
to result from mutations in genes such as FKRP, FKTN, or
ISPD.22,26 This brings the total number of genes in which
mutations can cause a dystroglycanopathy to 15. Although
many details of the complex glycosylation of a-DG are still
unknown, the picture becomes a little more complete with
each gene discovered.
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